Global Shigella Vaccines Market - 2023-2030

Overview

A Shigella vaccine is a vaccine designed to prevent shigellosis, a Vaccine caused by the shigella bacteria that can lead to moderate-to-severe diarrhoea and dysentery. The development of a Shigella vaccine is an important goal for public health, as it could have indirect effects on reducing the use of antibiotics and the consequent emergence of antimicrobial resistance.

There are four species of shigella, and three of these have multiple serotypes. This large number of Shigella serotypes presents a challenge for vaccine development since immunologic protection is largely serotype-specific. Shigella flexneri is the most important species globally, particularly in low-income countries, and consists of 15 serotypes, the most common of which is S. flexneri 2a, followed by 3a and 6.

Shigella sonnei has just one serotype and is the dominant species in countries that are undergoing industrial development. Shigella dysenteriae has 15 serotypes, the most significant being Shigella dysenteriae type 1, which was responsible for epidemic outbreaks with high-case fatality rates that seem to have disappeared in the 21st century. Shigella boydii, which has 19 serotypes, is responsible for a small minority of shigellosis cases and is mainly detected in South Asia.

Market Dynamics: Drivers and Restraints

Emerging vaccine pipeline

The development of highly effective and safe shigella vaccines would be a major accomplishment, but these vaccines will not sell themselves in the context of a crowded immunization schedule and many other competing interventions. There is still work to be conducted to determine if there is a compelling public health value proposition that can help stimulate the political will and grassroots advocacy often necessary for vaccine recommendations, purchase, and adoption.

Market Dynamics: Restraint

Side effects of vaccines are one the key factors that hamper the market growth during the forecast period. Some of the side effects include soreness or swelling where the shot was given, fever, fussiness, loss of appetite, tiredness, and vomiting. In the case of Influenza live vaccine, vomiting, muscle aches, fever, sore throat, and cough are other possible side effects. These side effects are limiting the market growth.

Segment Analysis

The global shigella vaccine pipeline is segmented based on vaccine type, age group, end-user and region.

The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% of the market share

The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% and it is expected to be dominated during the forecast period. Live attenuated vaccines are designed using weakened or attenuated forms of the pathogen. In the case of Shigella vaccines, live attenuated strains of the bacteria are used. These attenuated strains have been modified so that they are less virulent (less capable of causing Vaccine) compared to the wild-type, or naturally occurring, strains of Shigella.

For instance, according to clinical trails.gov on October 12, 2022, National Institute of Allergy and Infectious Vaccines (NIAID) started a clinical study on A Double-Blind Placebo-Controlled Randomized Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. sonnei 53G in Healthy Adults where it is currently under Phase 2 trials and estimated to complete its studies by July 2024.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like ongoing clinical trials, improved healthcare infrastructure in this region, research and development activities and a large number of biotechnological companies. The development of products and approval of vaccine products helps this region to have the highest market share during the forecast period.

For instance, according to clinicaltrial.gov on September 29, 2022, the University of Maryland, Baltimore started a clinical studies on Study of the Safety, Tolerability, and Immunogenicity of Oral Doses of CVD 1208S-122, a Prototype Attenuated Shigella Flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia Coli Antigens which is currently under phase 1 and this clinical trials are taking place in United States and studies are estimated to complete by September 2024.

COVID-19 Impact Analysis

There is limited information on the impact of COVID-19 on Shigella vaccines. However, existing COVID-19 booster vaccines are expected to provide reasonable protection against the virus. The development of a Shigella vaccine is an important goal for public health, as shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering

Market Segmentation

By Vaccine Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Whole-cell inactivated vaccines
• Subunit inactivated vaccines
• Conjugate Vaccines
• Others

By Age Group

• Infants
• Childrens

By End User

• Hospitals
• Clinics
• Non-Governmental Organizations (NGOs)
• Vaccination Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the shigella vaccine pipeline market include: LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Zhi Fei Biological, Vaxcyte, Inventprise and among others.

Key Developments

• In July 2023, GSK licensed out its Shigella vaccine candidate to LimmaTech Biologics, giving the Swiss biotech rights to further develop and eventually commercialize the quadrivalent bioconjugate investigational vaccine, LimmaTech is aiming to complete the Phase I/II clinical trial for this quadrivalent candidate and post data from this study within the year.
• In November 2020, Eveliqure announced the publication of key preclinical data for its clinical-stage vaccine candidate against Shigellosis and ETEC.

Why Purchase the Report?

• To visualize the global shigella vaccine pipeline market segmentation-based vaccine type, age group, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous shigella vaccine pipeline market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key vaccines of all the major players.

The global shigella vaccines pipeline market report would provide approximately 46 tables, 56 figures, and 165 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies